UBS Group’s CervoMed CRVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.6K | Buy |
5,239
+4,196
| +402% | +$21.9K | ﹤0.01% | 7906 |
|
|
2025
Q4 | $8.24K | Sell |
1,043
-2,333
| -69% | -$18.7K | ﹤0.01% | 8381 |
|
|
2025
Q3 | $27.3K | Sell |
3,376
-2,217
| -40% | -$19K | ﹤0.01% | 7961 |
|
|
2025
Q2 | $35.2K | Sell |
5,593
-1,194
| -18% | -$10.2K | ﹤0.01% | 8055 |
|
|
2025
Q1 | $62.1K | Sell |
6,787
-36,578
| -84% | -$139K | ﹤0.01% | 7415 |
|
|
2024
Q4 | $101K | Buy |
43,365
+40,828
| +1,609% | +$397K | ﹤0.01% | 6865 |
|
|
2024
Q3 | $37K | Buy |
2,537
+903
| +55% | +$14K | ﹤0.01% | 7016 |
|
|
2024
Q2 | $28K | Buy |
+1,634
| New | +$35.7K | ﹤0.01% | 7103 |
|
|
2023
Q3 | – | Sell |
-40
| Closed | -$200 | – | 9534 |
|
|
2023
Q2 | $200 | Sell |
40
-273
| -87% | -$1.59K | ﹤0.01% | 8397 |
|
|
2023
Q1 | $1.95K | Buy |
313
+98
| +46% | +$869 | ﹤0.01% | 8620 |
|
|
2022
Q4 | $1.63K | Sell |
215
-356
| -62% | -$2.97K | ﹤0.01% | 9827 |
|
|
2022
Q3 | $5K | Buy |
571
+284
| +99% | +$2.88K | ﹤0.01% | 9179 |
|
|
2022
Q2 | $3K | Buy |
+287
| New | +$3.56K | ﹤0.01% | 9293 |
|
|
2022
Q1 | – | Sell |
-702
| Closed | -$13.9K | – | 10336 |
|
|
2021
Q4 | $16K | Buy |
702
+674
| +2,407% | +$21.1K | ﹤0.01% | 8147 |
|
|
2021
Q3 | $1K | Sell |
28
-464
| -94% | -$19.3K | ﹤0.01% | 9160 |
|
|
2021
Q2 | $27K | Sell |
492
-1,014
| -67% | -$56K | ﹤0.01% | 7033 |
|
|
2021
Q1 | $104K | Buy |
1,506
+1,426
| +1,783% | +$120K | ﹤0.01% | 5933 |
|
|
2020
Q4 | $5K | Sell |
80
-251
| -76% | -$14.7K | ﹤0.01% | 7821 |
|
|
2020
Q3 | $21K | Sell |
331
-86
| -21% | -$6.54K | ﹤0.01% | 6269 |
|
|
2020
Q2 | $31K | Sell |
417
-411
| -50% | -$25K | ﹤0.01% | 6241 |
|
|
2020
Q1 | $20K | Buy |
828
+270
| +48% | +$8.19K | ﹤0.01% | 6486 |
|
|
2019
Q4 | $19K | Buy |
558
+486
| +675% | +$29.7K | ﹤0.01% | 6895 |
|
|
2019
Q3 | $10K | Buy |
+72
| New | +$11.6K | ﹤0.01% | 7156 |
|
|
2019
Q2 | – | Sell |
-47
| Closed | -$13K | – | 7897 |
|
|
2019
Q1 | $13K | Buy |
47
+25
| +114% | +$6K | ﹤0.01% | 6631 |
|
|
2018
Q4 | $3K | Sell |
22
-6
| -21% | -$2.05K | ﹤0.01% | 7708 |
|
|
2018
Q3 | $13K | Buy |
28
+23
| +460% | +$10.7K | ﹤0.01% | 7029 |
|
|
2018
Q2 | $3K | Sell |
5
-20
| -80% | -$11.8K | ﹤0.01% | 7626 |
|
|
2018
Q1 | $16K | Buy |
25
+18
| +257% | +$15.6K | ﹤0.01% | 6557 |
|
|
2017
Q4 | $9K | Buy |
7
+5
| +250% | +$8.1K | ﹤0.01% | 7080 |
|
|
2017
Q3 | $4K | Sell |
2
-3
| -60% | -$6.21K | ﹤0.01% | 7302 |
|
|
2017
Q2 | $12K | Buy |
5
+4
| +400% | +$12.9K | ﹤0.01% | 6639 |
|
|
2017
Q1 | $5K | Buy |
+1
| New | +$4.29K | ﹤0.01% | 6975 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7614 |
|
Other funds holding CRVO
VCM
XT
CFG
VFT
UBS Group's CRVO Position: Q1 2026 in Review
UBS Group increased its CervoMed (CRVO) stake by 402% in Q1 2026, buying an estimated $21.9K and bringing the position to 5,239 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7906.
UBS Group first reported a position in CRVO in Q1 2017 and has held it in 32 quarters since. The position peaked at $104K in Q1 2021. 36 funds tracked by Wall St. Rank hold CRVO as of Q1 2026.
- UBS Group held 5,239 shares of CervoMed worth $20.6K as of Q1 2026.
- UBS Group bought 4,196 CervoMed shares in Q1 2026, an estimated $21.9K.
- CervoMed made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7906 holding.
- UBS Group first reported a position in CervoMed in Q1 2017 and has held it in 32 quarters since.
- UBS Group's CervoMed position peaked at $104K in Q1 2021.
- 36 funds tracked by Wall St. Rank held CervoMed as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.